Income Statement
PRIME MEDICINE, INC.
PRME
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
4.63 | 2.98 | - | 0.00 |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
4.63 | 2.98 | - | - |
|
Operating Expenses
|
212.98 | 205.45 | 204.79 | 116.54 |
|
Research & Development
|
160.64 | 155.29 | 147.91 | 86.73 |
|
Selling, General & Administrative
|
52.35 | 50.16 | 43.39 | 29.82 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-208.35 | -202.47 | -204.79 | -116.54 |
|
Non-Operating Income
|
7.21 | 6.59 | 6.38 | -6.23 |
|
Interest Income
|
4.15 | 3.52 | - | - |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
0.15 | 0.04 | 8.76 | 1.90 |
|
Income Before Tax
|
- | - | - | - |
|
Income Tax Expense
|
- | 0.00 | -0.28 | -0.95 |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-201.14 | -195.88 | -198.13 | -121.82 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-201.03 | -196.34 | -200.14 | -114.32 |
|
Earnings Per Share (Basic)
|
-1.35 | -1.65 | -2.18 | -4.19 |
|
Diluted EPS
|
-1.35 | -1.65 | -2.18 | -4.19 |
|
Weighted Average Shares
|
148.76 | 118.60 | 90.97 | 33.89 |
|
Diluted Weighted Avg Shares
|
148.76 | 118.60 | 90.97 | 33.89 |
|
Comprehensive Income
|
-201.06 | -195.87 | -197.76 | -122.18 |